Trials / Completed
CompletedNCT02718430
VXM01 Phase I Study in Patients With Metastatic Colorectal Cancer With Liver Metastasis
VXM01 Phase I Study in Patients With Metastatic Colorectal Cancer With Liver Metastasis Under Second or Third Line Therapy to Examine Safety, Efficacy, and Immune Biomarkers After Treatment With VXM01
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Vaximm GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase I study in patients with metastatic colorectal cancer with liver metastasis under second or third line therapy to examine safety, efficacy, and immune biomarkers after treatment with VXM01
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VXM01 | Oral immunotherapy targeting VEGFR2 |
Timeline
- Start date
- 2016-02-01
- Primary completion
- 2018-03-01
- Completion
- 2018-03-01
- First posted
- 2016-03-24
- Last updated
- 2018-10-19
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT02718430. Inclusion in this directory is not an endorsement.